Meeting
2023 ASCO Annual Meeting
Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).
Authors
Matthew James Hadfield
RI Hosp Brown Univ, Providence, RI
Matthew James Hadfield , Nishant Gandhi , Alex Patrick Farrell , Christopher G. Azzoli , Ari M. Vanderwalde , Balazs Halmos , Stephen V. Liu , Wafik S. El-Deiry , Abdul Rafeh Naqash
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9120)
DOI
10.1200/JCO.2023.41.16_suppl.9120
Abstract #
9120
Poster Bd #
108
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2021 ASCO Annual Meeting
STK11/TP53 co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.
First Author: Abdul Rafeh Naqash
Poster
2023 ASCO Annual Meeting
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
First Author: Petros Christopoulos
Poster
2023 ASCO Annual Meeting
Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.
First Author: Hina Khan